Zymvol, a biotechnology company and a member of Catalonia.health, has announced a strategic collaboration with Olon, a global CDMO and generic manufacturer, to accelerate the adoption of biocatalysis as a scalable manufacturing solution for the pharmaceutical industry.

Predictive Enzyme Technology

The collaboration combines Zymvol's enzyme design platform, based on physics and AI, with Olon's industrial-scale biomanufacturing capabilities. This alliance creates a comprehensive route from enzyme discovery to ton-scale production, addressing the cost, timeline, and scaling challenges that have limited the industrial adoption of biocatalysis.

Under the agreement, Zymvol's enzyme optimization and discovery platform will support Olon's projects, while Zymvol will have access to Olon's manufacturing infrastructure, process development, and fermentation scaling capabilities for its programs, both self-funded and those carried out with clients.

Maria Fátima Lucas, CEO and Founder of Zymvol, stated: "Biocatalysis has been scientifically attractive for a long time, but its commercial adoption has been hindered by uncertainty, prolonged timelines, and scaling risk. Our physics- and AI-based methodology makes enzyme performance predictable before a project reaches the lab. By partnering with Olon, we can translate this digital certainty directly into industrial reality, significantly reducing time, cost, and risk from enzyme discovery to full-scale production."

This collaboration positions Zymvol to offer biocatalysis solutions that are faster to develop and commercially viable for the pharmaceutical and chemical sectors, which face growing pressure in terms of efficiency, sustainability, and supply chain resilience.